Kiniksa Pharmaceuticals International, Plc (KNSA) Stock Price & Analysis
Kiniksa Pharmaceuticals International, Plc (KNSA) fell 0.69% to USD 48.7 as of June 10, 2026 at 02:24 UTC, according to Nexqual real-time market data.
KNSA last closed at USD 49.04; the session ranged USD 48.49–50.72 on volume of 507,575 shares. Market capitalization is $3.75B, with a 52-week range of USD 26.27–59.87 (NMS). Source: Nexqual, June 10, 2026 at 02:24 UTC.
Key Statistics (as of June 10, 2026 at 02:24 UTC)
| Price | USD 48.7 |
|---|---|
| Change | ▼ 0.69% (down) |
| Previous Close | USD 49.04 |
| Open | USD 49.68 |
| Day Range | USD 48.49 – 50.72 |
| 52-Week Range | USD 26.27 – 59.87 |
| Volume | 507,575 shares |
| Market Cap | $3.75B |
| Exchange | NMS |
Technical Analysis (KNSA)
Nexqual's technical model rates KNSA "STRONG SELL" based on 0 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 02:24 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 48.76 (neutral) |
| vs SMA50 | Below (USD 50.5) |
| MACD | -1.07 (negative) |
Analyst Ratings (KNSA)
Wall Street analysts rate KNSA "Strong Buy" based on 8 analysts, with a mean price target of USD 63.5 (range USD 57–72), per Nexqual as of June 10, 2026 at 02:24 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 8 |
| Mean Target | USD 63.5 |
| High Target | USD 72 |
| Low Target | USD 57 |
| Buy / Hold / Sell | 8 / 0 / 0 |
Earnings (KNSA)
| Next Earnings Date | 2026-07-28 |
|---|---|
| EPS Estimate | USD 0.3 |
| Revenue Estimate | $226.53M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.27 vs est 0.16 ▲ beat |
| 2025-12-31 | USD 0.17 vs est 0.4 ▼ miss |
| 2025-09-30 | USD 0.23 vs est 0.37 ▼ miss |
| 2025-06-30 | USD 0.23 vs est 0.26 ▼ miss |
Source: Nexqual, June 10, 2026 at 02:24 UTC.
Financials & Fundamentals (KNSA)
| Total Revenue | $754.04M |
|---|---|
| Revenue Growth (YoY) | +55.50% |
| Gross Margin | +54.65% |
| Operating Margin | +13.66% |
| Profit Margin | +9.69% |
| ROE | +13.74% |
| Debt / Equity | 1.49 |
| Current Ratio | 3.79 |
| Total Cash | $468.09M |
| Total Debt | $9.03M |
| Free Cash Flow | $117.57M |
Source: Nexqual, June 10, 2026 at 02:24 UTC.
Financial Health Score (KNSA)
Nexqual rates Kiniksa Pharmaceuticals International, Plc's overall financial health "Strong" across five dimensions, as of June 10, 2026 at 02:24 UTC.
| Growth | Strong — Revenue +60% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 55%, operating 14% |
| Balance Sheet | Strong — $468M cash vs $9M debt, net cash position |
| Cash Flow | Strong — FCF $118M, 17% margin |
| Efficiency | Mixed — ROE 14%, ROA 8.2% |
Ownership (KNSA)
| Insider Ownership | +3.58% |
|---|---|
| Institutional Ownership | +102.77% |
| Shares Outstanding | 46.30M |
| Float | 39.32M |
| Short % of Float | +8.01% |
Source: Nexqual, June 10, 2026 at 02:24 UTC.
Leadership (KNSA)
Kiniksa Pharmaceuticals International, Plc is led by Sanj K. Patel (age 56), CEO & Chairman of the Board, per Nexqual as of June 10, 2026 at 02:24 UTC.
| CEO & Chairman of the Board | Sanj K. Patel (age 56) |
|---|---|
| Executive VP & CFO | Mark A. Ragosa C.F.A. (age 51) |
| Executive VP, COO & Principal Operating Officer | Ross Michael Moat (age 45) |
Major Backers & Investors (KNSA)
Notable institutional backers of Kiniksa Pharmaceuticals International, Plc include FMR, LLC, Rubric Capital Management LP, Fidelity, according to Nexqual as of June 10, 2026 at 02:24 UTC.
Active Investors
| Investor | Stake |
|---|---|
| FMR, LLC | 16.93% |
| Rubric Capital Management LP | 9.3% |
| Fidelity | 8.54% |
| Baker Bros. Advisors, LP | 7.01% |
| Tang Capital Management, LLC | 5.61% |
| Acadian Asset Management. LLC | 3.32% |
| Morgan Stanley | 2.48% |
| Shaw D.E. & Co., Inc. | 2.38% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 14.58% |
Source: Nexqual, June 10, 2026 at 02:24 UTC.
From Kiniksa Pharmaceuticals International, Plc's Latest SEC 10-K Filing (filed 2026-02-24)
Key Strengths & Strategy (as disclosed to the SEC)
- Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally.
- The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis.
- It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CRNX | Crinetics Pharmaceuticals, Inc. | USD 34.97 | ▲ 6.23% |
| MIRM | Mirum Pharmaceuticals, Inc. | USD 95.48 | ▲ 2.14% |
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 87.86 | ▲ 1.69% |
| KRYS | Krystal Biotech, Inc. | USD 309.75 | ▲ 2.91% |
| REPL | Replimune Group, Inc. | USD 9.24 | ▼ 2.43% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:24 UTC. This page is informational and not investment advice.